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Radiolabelling an 18F biologic via facile IEDDA “click” chemistry on 
the GE FASTLab™ platform
Louis Allott1,3,4†, Ala Amgheib1,2†, Chris Barnes1, Marta Braga1, Diana Brickute1, Ning Wang1, Ruisi 
Fu1, Sadaf Ghaem-Maghami1,2 and Eric O. Aboagye1*
The use of biologics in positron emission tomography (PET) imaging is an important area of radiopharmaceutical 
development and new automated methods are required to facilitate their production. We report an automated 
radiosynthesis method to produce a radiolabelled biologic via facile inverse electron demand Diels-Alder (IEDDA) “click” 
chemistry on a single GE FASTLab™ cassette. We exemplified the method by producing a fluorine-18 radiolabelled 
interleukin-2 (IL2) radioconjugate from a trans-cyclooctene (TCO) modified IL2 precursor. The radioconjugate was 
produced using a fully automated radiosynthesis on a single FASTLab™ cassette in a decay-corrected radiochemical yield 
(RCY, d.c.) of 19.8 ± 2.6% in 110 min (from start of synthesis); the molar activity was 132.3 ± 14.6 GBq/mol. The in vitro 
uptake of [18F]TTCO-IL2 correlated with the differential receptor expression (CD25, CD122, CD132) in PC3, NK-92 and 
activated human PBMCs. The automated method may be adapted for the radiosynthesis of any TCO-modified protein via 
IEDDA chemistry.
Introduction
Positron emission tomography (PET) is a functional molecular 
imaging modality used in the clinic to inform the diagnosis and 
progression of diseases like cancer.1,2 Targeted 
radiopharmaceuticals are required to trace or quantify 
biological processes associated with disease states (i.e. energy 
metabolism, proliferation, receptor expression) and an active 
research and development community is working towards 
producing such molecules for clinical translation. The 
transition of radiopharmaceuticals from the laboratory bench 
into clinical evaluation requires automated radiosynthesis 
under good manufacturing processes (GMP) conditions, to 
produce consistent sterile patient doses and reduce radiation 
exposure to production staff.3,4 As we ask evermore complex 
clinical questions, the development of new 
radiopharmaceuticals with intricate and sensitive chemical 
structures often provide answers; however, their efficient 
radiolabelling and automated production can be challenging. 
The implementation of radiolabelled peptides and proteins as 
targeting vectors in nuclear medicine is increasing owed to 
their unparalelled targeted affinity, selectivity and specificity;5 
however, few GMP compatible automated radiolabelling 
processes have been reported.6,7 We and others have 
developed various automated radiolabelling procedures for 
their production, including an automated procedure for 
copper catalysed azide alkyne cycloaddition (CuAAC) “click” 
chemistry for an 18F somatostatin analogue ([18F]FET-AG-
Figure 1. Schematic representation of fluorine-18 prosthetic group (PG) 
strategies for radiolabelling peptides and proteins.
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TOCA) which has progressed into Phase III clinical trials;8,9 a 
generic automated radiolabelling procedure for the 
aluminium-[18F]fluoride method to produce [18F]NOTA-
octreotide and [18F]NOTA-RGDfK radioconjugates and an 
automated procedure for solid-supported reductive amination 
radiochemistry.10–12  
Fluorine-18 prosthetic group (PG) strategies, where a small 
organic molecule is radiolablled independently of a 
biomolecule and later conjugated under mild conditions, can 
be used to maintain the structural integrity of the protein 
(Figure 1).13  Reported PG strategies and their automated 
procedures support the production of radioconjugates from  
micromolar (mol) quantities of biomolecule precursors, 
typically peptides (ca. 1 – 4kDa) which are inexpensive to 
synthesise in multi-milligram quantities.8,14 Targeted proteins 
(>5kDa) are often made in small batches (g to mg) as they are 
expensive to produce and are therefore radiolabelled at low 
total protein quantities (g, nmol) to reduce cost, but also 
because of the challenge in separating the radioconjugate 
from the unlabelled biomolecule, which can negatively 
influence molar activity (Am). There are few examples where 
targeted proteins are radiolabelled with an 18F-PG using fully 
automated procedures, and to the best of our knowledge, no 
examples where an entire radiosynthesis has been 
accomplished on a single cassette-based automated platform.
The biologic interleukin-2 (IL2) is of great interest as it 
targets the IL2-receptor (IL2R) expressed on activated T-cells. 
IL2R is comprised of IL2Rα (CD25), IL2Rβ (CD122) and IL2Rγ 
(CD132) subunits resulting in a variable affinity receptor.15 
Recombinant IL2 is commercially available as Proleukin™ 
(Novartis) and is used in the treatment of metastatic renal cell 
carcinoma and melanoma; typically administered as 
intravenous infusion or subcutaneous injection.16,17 Targeting 
the high affinity CD25 using IL2-based radioconjugates could 
potentially enable the detection of T-cell activation in solid 
tumours and, thus monitoring of response to 
immunotherapy.3,18,19 Gialleonardo et al (2012) reported a 
fluorine-18 IL2 radioconjugate ([18F]FB-IL2) which was 
synthesised using the N-succinimidyl-4-[18F]fluorobenzoate 
([18F]SFB) prosthetic group and later translated the 
radiochemistry into a GMP compatible production to support a 
clinical trial.6,20 Unfortunately, the lengthy radiosynthesis of 
[18F]SFB and the complexity of radiolabelling proteins using 
automated platforms required the use of two hot-cells and 
two automated radiosynthesis platforms. This process is not 
attractive to GMP production facilities. DeVries et al are 
addressing this concern and have developed metal-based 
radiolabelling strategies;21 but the question remains, if we can 
develop an 18F-PG strategy for the automated production of 
proteinious radioconjugates using a single cassette-based 
platform?   
The use of inverse electron demand Diels-Alder (IEDDA) 
chemistry to radiolabel a protein modified with a trans-
cyclooctene (TCO) moiety by ligating an 18F-tetrazine 
prosthetic group has been reported but an automated 
radiolabelling procedure has not been described.22 We report 
a fully automated 18F-PG strategy used to radiolabel TCO-
modified IL2 using IEDDA “click” chemistry. We believe this to 
be the first fully automated radiosynthesis of an IL2 
radioconjugate using an 18F-PG strategy on a single cassette-
based automated platform. The reported method may be 
adapted for use in radiolabelling any TCO-modified protein and 
“noteworthy considerations” are suggested throughout for 
translating this work to other biomolecules of interest. 
Experimental Procedures
Detailed materials and methods appear in the ESI. 
Radiochemical yields (RCY) are decay corrected (d.c.) to the 
start of radiosynthesis, in line with the “Consensus 
nomenclature rules for radiopharmaceutical chemistry – 
Setting the record straight”.23 Experimental procedures for the 
synthesis of compounds 1 – 5 and their characterisation by 
NMR and mass spectrometry appear in the ESI (Figure S1 – 12). 
Experimental procedure for in vitro metabolite analysis, cell 
culture and flow cytometry are reported in the ESI (Figure S22 
– 24).
Materials and methods. 
Anhydrous solvents and reagents were purchased from Sigma 
Aldrich (Gillingham, UK) and were used without additional 
purification. TCO-PEG4-NHS ester was purchased from Jena 
Bioscience (Jena, Germany). Proleukin™ was precured from 
Novartis Pharmaceuticals (London, UK). Flash column 
chromatography purification was performed on silica gel 
(Merck Kieselgel 60 F254 320–400 mesh). [18F]Fluoride was 
produced by a GE PETtrace cyclotron by 16 MeV irradiation of 
enriched [18O]H2O target, supplied by Alliance Medical 
Radiopharmacy Ltd (Warwick, UK). Automated radiosynthesies 
were performed using the GE FASTlab™ automated synthesis 
module (GE Healthcare Life Sciences, Amersham, UK). Solid 
phase extraction (SPE) cartridges were purchased from Waters 
(Elstree, Hertfordshire, UK) and used according to the 
manufacturers recommended guidelines. Semi-preparative RP-
HPLC was performed using a Shimadzu LC20-AT pump 
attached to a custom-built system, equipped with an Agilent 
Eclipse XDB-C18, 5 (250 x 9.4 mm) column using an isocratic 
mobile phase of MeCN (44%), H2O (56%) and 0.1% H3PO4 (14.8 
M) at a flow rate of 3 mL/min. Reaction efficiency and 
radioactive product identity was determined by RP-HPLC using 
an Agilent 1200 series instrument connected to a flow-ram 
detector (Lablogic, Sheffield, UK). This study used a PC3 cell 
line, gifted from Prof. Charlotte Bevan, Imperial College 
London and a NK-92 cell line purchased from ATCC 
(Teddington, UK).
Synthesis of TCO-PEG4-IL2. To each of three vials of Proleukin™ 
(18 ×106 IU, ~1.3 mg) was added water (250 µL), which was 
combined into a single vial to give a Proleukin™ (3.96 mg, 255 
nmol) in water (750 µL, 5.28 mg/mL). A Zeba™ Spin Desalting 
Column (7 kDa MWCO, 5 mL) was equilibrated with a pH 8 
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bioconjugation solution containing NaHCO3 (0.1 M) and SDS 
(0.05% w/v), as per the manufacturers recommended 
equilibration protocol. The Proleukin™ solution was exchanged 
into the NaHCO3/SDS solution and protein recovery was 
determined to be quantitative by UV-Vis (Nanodrop). A fresh 
stock of TCO-PEG4-NHS ester was prepared in DMF (255 
nmol/µL) and an aliquot (10.6 µL) was added to the Proleukin™ 
solution in a 12:1 ratio (TCO-PEG4-NHS ester : Proleukin™). The 
reaction was gently shaken for 2 h at ambient temperature. A 
Zeba™ Spin Desalting Column (7 kDa MWCO, 5 mL) was 
equilibrated in a storage solution containing SDS (0.05% w/v) 
and PSB. The Proleukin™ reaction mixture was loaded onto the 
column and purified. The resulting solution contained TCO-
PEG4-IL2, and the protein content was determined by UV-Vis 
spectroscopy (nanodrop) and BCA assay; aliquots of 200 µg 
were prepared for radiolabelling and stored at -20 °C. The 
number of TCO moieties per molecule of IL2 was determined 
by nanodrop and the full experimental procedure described in 
the ESI.
Automated radiosynthesis of [18F]FB-Tz. A previously reported 
radiosynthesis for automating reductive amination radiochemistry 
using solid-supported cyanoborohydride cartridges was adapted for 
the synthesis of [18F]FB-Tz.10 In summary, [18F]FBA was synthesised 
to which precursor 1 (35 mg) in MeCN (1.5 mL) and triethylamine 
(40 µL) was added. After warming and reduction using the BH3CN- 
cartridge following the published protocol, the reaction mixture 
was diluted in phosphate buffer (5 mL, pH 2.4) and purified by semi-
preparative HPLC. The cut peak was diluted in phosphate buffer (45 
mL, pH 2.4) and trapped on a tC18 plus SPE cartridge which was 
subsequently flushed with nitrogen. [18F]FB-Tz was eluted with 
EtOH. 
Automated radiosynthesis of [18F]FBoxTz. A detailed description of 
the automated radiosynthesis setup can be found in the supporting 
information (ESI Figure S14). This radiosynthesis required the water 
bag (position 15) to be modified to include H3PO4 (0.1% v/v) and 
SDS (0.05% w/v). A GE FASTLab™ system was programmed to trap 
aqueous [18F]fluoride from [18O]water on a QMA bicarbonate 
cartridge (position 4-5) which was eluted into the reactor using a 
solution containing KHCO3 (3.5 mg/mL, H2O 200 µL) and Kryptofix-
222 (6.0 mg/mL, MeCN 800 µL). The [18F]fluoride was dried at 120 
°C (9 min) and 70 °C (5 min) before the addition of 4-formyl-N,N,N-
trimethylanilinium triflate (3 mg in 1.4 mL MeCN). The reaction was 
heated to 90 °C for 6.6 min to synthesise [18F]FBA. After cooling, a 
solution containing 3 (8 mg in 1 mL MeCN) and aniline 
hydrochloride (6 mg in 400 µL H2O) was added to the [18F]FBA in the 
reactor and warmed to 40 °C for 10 min to synthesise [18F]FBoxTz. 
The reaction mixture was diluted for semi-preparative HPLC 
purification (7.5 mL H2O + 0.1% H3PO4). The isolated [18F]FBoxTz (tR 
= 21 – 24 min) was cut into a vial containing a dilution mixture (35 
mL H2O + 0.1% H3PO4) and returned to the FASTLab™ for trapping 
on a tC18 SPE. The trapped [18F]FBoxTz was washed with the water 
bag solution (2 × 5 mL) and dried under N2. [18F]FBoxTz was eluted 
from the SPE cartridge in ethanol. The sequence continued for the 
automated radiosynthesis of [18F]TTCO-IL2.
Automated radiosynthesis of [18F]TTCO-IL2. [18F]FBoxTz was eluted 
into an off-board reactor with ethanol (500 µL) containing TCO-
PEG4-IL2 (200 µg, 2 – 3 mg/mL) and allowed to react for 15 min at 
ambient temperature. The reaction mixture containing [18F]TTCO-
IL2 was diluted with the water bag solution (9 mL) and loaded onto 
a tC2 SPE cartridge. Unreacted [18F]FBoxTz was eluted to waste by 
washing with a 50% EtOH solution. The desired [18F]TTCO-IL2 was 
eluted from the cartridge using 100% EtOH. The minimum SA was 
determined by the following equation: [Radioactivity in product vial 
(MBq)]/200 µg = Specific Activity, SA (MBq/µg); or by integrating 
the area under the radioactive peak at the 210 nm wavelength and 
comparing area to a reference standard of TCO-PEG4-IL2. 
Radiochemical purity was determined by radio-HPLC (tR = 08:48 
mm:ss) and radio-TLC (Rf = 0). 
Radiochemical stability of [18F]TTCO-IL2. A vial of [18F]TTCO-IL2 in 
the standard formulation was synthesised using the automated 
procedure starting from a high activity of [18F]fluoride (19.6 ± 2.4 
GBq, n = 3). An aliquot of radioactivity (4.4 ± 0.9 MBq) was diluted 
in 0.1% TFA (500 uL) and analysed by HPLC for each 0, 0.5, 1, 2, 3, 4, 
5 and 6 h time point. Radio-TLC was also used (iTLC silica sheet, 
mobile phase: 2:1 EtOAc:Hexane) for 1, 2, 3, 4, 5 and 6 h time 
points. The experiment was repeated three times from separate 
productions. 
In vitro Radioactive Uptake. To assess the in vitro uptake of 
[18F]TTCO-IL2, 72 h PHA-stimulated PBMCs (approximately 1x106 
cells/tube) were incubated with 0.74 MBq of [18F]TTCO-IL2 at 37 C 
and 5% CO2. PC3 cells were seeded in a 6-well plate at a seeding 
density of 0.3x106 cells/well 24 hours prior to administration of 
[18F]TTCO-IL2. Approximately 1x106 of NK-92 cells were incubated 
with 0.74 MBq of [18F]TTCO-IL2 at room temperature. After 1 hour, 
cells were washed twice with 500 μL of ice-cold PBS and lysed with 
1 mL ice-cold RIPA buffer (ThermoFisher) for 10 minutes on ice. 
Cell-bound radioactivity was measured, and decay corrected using 
Packard Cobra II gamma counter (Perkin Elmer). The 
radiopharmaceutical uptake was normalised to total cellular 
protein. Uptake was expressed as % radioactivity/mg protein. To 
determine the effect of [18F]TTCO-IL2 on IL2R signalling, NK-92 cells 
were incubated with 0.74 MBq [18F]TTCO-IL2 or unlabelled 
recombinant IL2 ( 214 ng/mL) for 1 hour at 37 C and 5% CO2. Cells 
were washed as previously described and fixed with 4% 
paraformaldehyde for 20 minutes before proceeding with 
phosphorylated-STAT5 (Tyr694) analysis using flow cytometry. Data 
were summarised and analysed using Prism GraphPad 7 software. 
Statistical analysis was performed using an unpaired two-tailed t-
test. 
Results and Discussion
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The use and automation of 18F-PG strategies to radiolabel 
proteins is challenging for several reasons:
1. 18F-PG strategies can be challenging to synthesise. 
Depending on the PG, multistep radiosynthesis and 
purification are required to access the desired 18F-PG. The 
PG needs to be produced in high Am for radiolabelling 
biomolecules through second order reactions to avoid 
self-competition at reactive sites. 
2. 18F-PGs can be unstable. N-hydroxy succinimide esters 
(e.g [18F]SFB) rapidly hydrolyse in aqueous media at the 
pH required for efficient amide bond formation with 
lysine amino acids (8 – 9 pH). Competitive hydrolysis 
reduces the efficiency in radiolabelling the molecule of 
interest, impacting both radiochemical yield (RCY) and 
potentially, molar activity (Am).
3. Cassette-based automated platforms have a limited 
capacity. These platforms are primarily designed for 
small-molecule radiochemistry where SN2 18F-fluorination 
is followed by deprotection and a purification step; 
radiolabelling biomolecules through 18F-PG strategies is 
more complex in terms of i) number of synthetic steps, ii) 
types of purification strategy, iii) low reagent 
concentrations and thus iv) low volume reagent handling. 
“Click” chemistry has been proved to be an effective strategy 
for radiolabelling complex molecules.8,9,14,22,24,25 We proposed 
that the IEDDA “click” reaction could address each of these 
limitations and produce a fully automated single-cassette 
based method for radiolabelling biomolecules.22 Given the 
challenges faced in producing an efficient radiosynthesis of 
[18F]FB-IL2, and its clinical relevance, we developed an 
automated IEDDA “click” method to radiolabel a novel TCO-
modified IL2 conjugate (TCO-PEG4-IL2) that we produced for 
this project. 
Developing a TCO-modified IL2 conjugate.
The abundant availability of TCO reagents allowed for a simple 
route to accessing a TCO-containing IL2 precursor by 
conjugating commercially available TCO-PEG4-NHS ester to 
recombinant IL2 (Proleukin™). In brief, the lyophilised 
recombinant IL2 (1.3 mg vial) was reconstituted in water to a 
concentration of 5 mg/mL and exchanged into a sodium 
bicarbonate (0.1 M, pH 8) conjugation medium using Zeba™ 
spin desalting columns. The TCO-PEG4-NHS ester was added to 
the reaction mixture in a 12:1 molar ratio, similar to that used 
in the development of [99mTc]Tc-HYNIC-IL2.26 After gentle 
shaking for 2 hours at room temperature, the bioconjugate 
was purified by Zeba™ spin desalting column. The protein 
concentration was determined by bicinchoninic acid (BCA) 
assay and typical yields were ca. 60%. The average number of 
TCO moieties per molecule of IL2 was 0.74 ± 0.02, determined 
by UV-vis spectroscopy. The TCO-PEG4-IL2 bioconjugate was 
aliquoted into 1.5 mL microcentrifuge tubes for radiolabelling 
and stored at -20 °C. HPLC analysis of TCO-PEG4-IL2 resulted in 
a single peak at 08:18 mm:ss (ESI Figure S19).  
It was considered that functionalising IL2 with TCO-PEG4 
could change the biological properties of the protein. Prodrug 
strategies for IL2 have been developed by decorating the 
surface of the protein with large PEG chains to modulated the 
affinity, target selectivity and in vivo pharmacokinetics of the 
drug.27 Additionally, small modifications to the protein 
structure of IL2 have been reported to influence binding 
modes.28–30 To investigate the influence of our modification to 
IL2, the in vitro biological properties of [18F]TTCO-IL2 have 
been evaluated and are reported later.   
Noteworthy Consideration: site-specific modification of 
proteins can potentially overcome poor biological 
performance by producing discrete molecular structures 
where key binding sites remain intact.31–33
Development of a convenient 18F-tetrazine prosthetic group. 
There are many examples of 18F-radiolabelled tetrazines 
produced by different radiosynthesis methods and in variable 
RCY, fuelled by the increased interest in pre-targeted immuno-
PET;34–37 however, new 18F-tetrazines were developed 
specifically as PGs that could be accessed in a high RCY, Am and 
in few radiosynthetic steps. The direct 18F-fluorination of a 
tetrazine is notoriously difficult due to instability in the harsh 
reaction conditions required to promote nucleophilic 
chemistry. The modular assembly of two novel 18F-tetrazines 
was therefore favoured and reductive amination chemistry, as 
well as oxime chemistry, were evaluated (Scheme 1A). The 
radiosynthesis of N-(4-[18F]fluorobenzyl)-1-(4-(6-methyl-
1,2,4,5-tetrazin-3-yl)phenyl)methanamine ([18F]FB-Tz) used 
simple reductive chemistry reaction between an amine-
containing tetrazine (1) and 4-[18F]fluorobenzaldehyde 
([18F]FBA). The automated radiochemistry was derived from 
our previously published work on the development solid-
supported cyanoborohydride reducing agent cartridges.10 
[18F]FB-Tz was successfully produced in a 8.7 ± 1.1 % RCY (d.c.) 
Scheme 1. A) Two radiosynthetic routes to 18F-tetrazines: N-(4-[18F]fluorobenzyl)-1-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl)methanamine ([18F]FB-Tz) and E-2-
(((4-[18F]fluorobenzylidene)amino)oxy)-N-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)benzyl)acetamide ([18F]FBoxTz). Reaction conditions: i) [18F]FBA, solid-supported 
cyanoborohydride cartridge, MeCN/H2O; ii) [18F]FBA, aniline hydrochloride, MeCN/H2O, 40 °C, 10 min. B) The reaction between [18F]FBoxTz and TCO-PEG4-IL2 to 






































RCY = 31.6  9.9%
RCP >98%




























































































































































Journal Name  ARTICLE
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 5
Please do not adjust margins
Please do not adjust margins
using a fully automated procedure in 80 min. To compare the 
influence of reaction chemistry on the overall radiochemical 
properties of the PG, we developed E-2-(((4-
[18F]fluorobenzylidene)amino)oxy)-N-(4-(6-methyl-1,2,4,5-
tetrazin-3-yl)benzyl)acetamide ([18F]FBoxTz) to utilise oxime 
chemistry. 
[18F]FBoxTz removed the need for an on-board reducing 
agent by exploiting oxime ligation between the aminoxy 
functional group and [18F]FBA. The radiochemistry was simple 
to automate and produced [18F]FBoxTz in a 31.6 ± 9.9 % RCY 
(d.c.) in 85 min. In brief, [18F]fluoride was dried and [18F]FBA 
synthesised and precursor 3 added along with aniline 
hydrochloride as a catalyst. The resulting [18F]FBoxTz was 
purified by semi-preparative HPLC and the radioactive product 
reformulated using a tC18 solid phase extraction (SPE) 
cartridge, which was eluted with ethanol. The [18F]FBoxTz 
radiosynthesis not only gave a higher RCY (d.c.) compared to 
[18F]FB-Tz (ca. 32% vs. 9%), the purity profile was much 
improved and therefore fewer competing tetrazine impurities 
would be introduced into the IEDDA “click” step. The low RCY 
of [18F]FB-Tz was likely due to instability of the tetrazine under 
reducing conditions, converting into an unreactive 
dihydrotetrazine.38 Additionally, the radiosynthesis used fewer 
positions on the FASTLab™ cassette which would allow greater 
flexibility in implementing the entire radiolabelling method 
onto the single cassette (Figure 2). 
Noteworthy Consideration: with advances in late-stage 
fluorination reactions, it will likely be possible to synthesise 
an 18F-tetrazine with appropriate characteristics (RCY, Am) in 
a single step.39,40 This would further reduce the overall 
complexity of the sequence and allow for even more flexibility 
in the cassette and sequence design. A semi-preparative HPLC 
system is not included as standard with the FASTLab™ 
platform and here, a custom-build HPLC module and 
complementary software was used to purify [18F]FBoxTz; the 
loading of crude reaction mixture was performed by syringe 
using the FASTLab™ cassette and sequence. The feasibility of 
this will depend upon the HPLC module available, but should 
be comparable if the system contains a luer-lock fitted 
injection loop (≥10 mL).
Automating the IEDDA “click” reaction.
With an efficient 18F-tetrazine radiosynthesis developed, the 
cassette and sequence were expanded to automate the IEDDA 
“click” chemistry (Figure 2). This reaction occurs quickly at 
ambient temperature, at low concentration of reagents and in 
the absence of metal catalysts meaning there were few 
variables to optimise other than the quantity of TCO-PEG4-IL2 
precursor. A key radiochemical parameter for IL2 
radioconjugates is a high final Am; IL2 is an agonist and there 
are reports of effective low-dose IL2 therapy (100 g per 
dose).41,42 There is a precedent for PET and SPECT IL2 
radioconjugates to been administered at <50 g of total 
protein per dose, therefore we aimed to develop a similar 
protocol for this IL2 radioconjugate.3,18,19,43 The automated 
procedure and cassette layout for [18F]FBoxTz was adapted to 
elute the 18F-PG in ethanol into an external Wheaton vial 
containing the TCO-PEG4-IL2 precursor which reacted for 10 
min before purification; purification of the radioconjugate is 
described later in this manuscript. The efficiency of the IEDDA 
“click” reaction was monitored by HPLC and radio-TLC. The full 
radiosynthesis is described in the supporting information (ESI 
Figure S14). 
Noteworthy consideration: IL2 is a lipophilic protein and is 
stable in 100% ethanol therefore, no special attention was 
paid to the organic solvent content of the IEDDA “click” 
Figure 2. A schematic representation of the GE FASTLab™ cassette developed for the automated radiosynthesis of [18F]TTCO-IL2; a detailed description of the 
cassette setup appears in the supporting information (ESI Figure S14).
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reaction. Depending on the biomolecule in question, this may 
be critical to its stability. It is possible to reduce the elution 
volume by using smaller SPE cartridges and more carefully 
considered elution volumes. 
A maximum quantity of TCO-PEG4-IL2, 200 g per 
radiolabelling reaction was investigated to produce clinically 
relevant Am of [18F]TTCO-IL2. The automated synthesis 
produced [18F]TTCO-IL2 in 19.8 ± 2.6 % RCY (d.c.) (n = 14) 
within 110 min from the start of synthesis in >98% RCP. The 
radiochemical yield was not influenced by the starting activity 
of [18F]fluoride, however the molar activity increased linearly 
(R2 = 0.9744) with starting activities ranging from 1.0 – 21.8 
GBq (ESI, Figure S15). Three productions using 19.6 ± 2.4 GBq 
of [18F]fluoride gave an Am of 132.3 ± 14.6 GBq/µmol (SA: 8.5 ± 
0.8 MBq/µg) which is sufficient for biological evaluation and 
clinical studies; in theory, a patient dose could be administered 
2.5 h post radiosynthesis and still be within the 50 µg/dose IL2 
limit. The recovery of the radioconjugate from the cassette 
was high, with negligible radiolabelled protein binding to 
plastic consumables was noted.
 
Noteworthy consideration: Conditioning plastics for low 
protein binding with human serum albumin (HSA) or bovine 
serum albumin (BSA) is a simple solution to implement to aid 
recovery of a radioconjugate.
It was assumed that reducing the quantity of TCO-PEG4-IL2 
precursor from 200 g to 100 g would improve the Am if the 
IEDDA “click” efficiency remained the same. This hypothesis 
was tested by reducing the precursor quantity and reaction 
concentration by half; Am did not improve as the overall RCY 
was diminished by 50% (Table 1). A TCO-PEG4-IL2 precursor 
quantity of 200 g was maintained for all further experiments.
Purification of [18F]TTCO-IL2.
Selecting an appropriate purification strategy for a 
radioconjugate is specific to the physicochemical properties of 
the protein of interest. IL2 radioconjugates have been 
effectively purified by tC2 SPE, a strategy made possible by the 
stability of the biomolecule to high concentrations of organic 
solvents.6,44 This is not the case for all proteins, which can 
denature under such conditions; however, some small protein 
fragments (e.g. Affibody molecules) and DNA aptamers can 
tolerate high concentrations of organic solvent.22,45 [18F]TTCO-
IL2 was purified by tC2 by adapting previously described 
procedures.6,46,47 This method removed unreacted [18F]FBoxTz 
and small-molecule impurities independently of [18F]TTCO-IL2, 
which was finally eluted into a formulation vial in >98% 
radiochemical purity (RCP). 
Noteworthy Consideration: while an SPE strategy was 
adapted for our application, there is sufficient space on the 
FASTLab™ cassette to incorporate a second semi-preparative 
HPLC purification using a biocompatible mobile phase. 
Alternatively, the automation of a size-exclusion purification 
method using commercially available luer-lock syringe driven 
cartridges may provide an elegant alternative.
Summary of complete automated radiosynthesis
The automated radiosynthesis was simple to set up using 
commercially available components and reliably produced 
large batches of [18F]TTCO-IL2 (1.7 ± 0.2 GBq, n = 3). The 
radiosynthesis from [18F]fluoride to formulated [18F]TTCO-IL2 
was complete in 110 min and the product was radiochemically 
stable (99.9 ± 0.1 %) for the duration of testing (6 h) (ESI Figure 
S20-21). The identity of [18F]TTCO-IL2 was confirmed by radio-
HPLC and a representative chromatogram is shown in Figure 3. 
The RCY (d.c.) was 19.8 ± 2.6% (n = 14) and the molar activity 
was 132.3 ± 14.6 GBq/mol from 19.6 ± 2.4 GBq of 
[18F]fluoride. Since completing this study, we have successfully 
produced GMP grade precursor 3 through a commercial 
research organisation to support future clinical translation of 
this strategy. 
In vitro evaluation of [18F]TTCO-IL2.
[18F]TTCO-IL2 was evaluated in vitro against IL2R positive and 
negative cell lines, to confirm the retention of biological 
Figure 3. Representative HPLC chromatogram showing [18F]TTCO-IL2 (grey 
line) co-injected with non-reactive TCO-PEG4-IL2 (red line).
Table 1. Key radiochemical parameters (SA, Am and RCY) for the radiosynthesis of 
[18F]TTCO-IL2, including the influence of TCO-PEG4-IL2 precursor quantity. Data 
presented as mean ± SD and experiments were performed in a: n = 3 and b: n=11 
repeats.
Entry 1 Entry 2 Entry 3
TCO-PEG4-IL2 (g) 100 a 200 b 200 a
Starting activity
of [18F]fluoride (GBq)
7.5 ± 1.5 6.9 ± 2.2 19.6 ± 2.4
Specific Activity 
(MBq/g)
3.8 ± 1.5 3.5 ± 1.2 8.5 ± 0.8
Molar Activity 
(GBq/mol)
59.4 ± 22.7 54.3 ± 18.0 132.3 ± 14.6
Radiochemical Yield 
(% RCY, d.c.)
5.1 ± 1.6 10.2 ± 1.2 8.7 ± 0.7
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activity after radiolabelling. This was important to assess if any 
component of the conjugation or radiolabelling procedure had 
negatively influenced the integrity of IL2; additionally, this is 
the first time a TCO modified IL2 conjugate has been described 
and it was important to determine if TCO-PEG4 had perturbed 
its receptor recognition. 
The in vitro uptake of [18F]TTCO-IL2 in cell lines with 
differential IL2R expression was investigated (Figure 4A&B). 
NK-92 cells and human PBMCs were stimulated to upregulate 
CD25 and consequently form the high affinity IL2R. PC3 
prostate cancer cell line did not express CD25 and CD122, and 
therefore was used as a negative control.  IL2R expression was 
confirmed by FACS analysis (Figure 4C). The in vitro uptake of 
[18F]TTCO-IL2 is in agreement with the differential expression 
of CD25 in stimulated PBMCs, NK-92 and PC3 cells, and 
comparable to other IL2-based PET probes.21 Uptake was low 
in CD25 and CD122 negative PC3 cells indicating negligible 
non-specific binding. Analysis of phosphorylated STAT5 
(Tyr694), critical for IL2 signalling, in NK-92 cells incubated 
with a dose of [18F]TTCO-IL2 (which also contains TCO-PEG4-
IL2) demonstrated insignificant effect on STAT5 
phosphorylation compared to recombinant IL2 at the same 
concentration (Figure S26). This suggests that [18F]TTCO-IL2 
may not elicit an immune response when administered at a 
low concentration. The metabolic profile of [18F]TTCO-IL2 was 
determined in vitro using human liver microsomes (HLM) and 
mouse liver S9. The radioconjugate was stable (ca 92% parent 
remaining in 60 min) for both species, although extraction 
efficiencies were low (19.5 ± 1.5% for HLM and 27.5 ± 3.3% for 
mouse liver S9), likely resulting from precipitation or 
aggregation of [18F]TTCO-IL2 caused by the extraction process 
from the biological milieu (Figure S22).
Conclusion
To exemplify the utility of adapting IEDDA “click” chemistry to 
radiolabel proteins in a fully automated, single-cassette based 
procedure, we describe a method for radiolabelling a TCO-
modified IL2 protein using the GE FASTLab™ platform. 
[18F]TTCO-IL2, a biologically active radioconjugate towards the 
IL2R was produced in 110 min from a single-cassette 
radiosynthesis. The in vivo evaluation of [18F]TTCO-IL2 is 
underway, but early data suggests uptake in target enriched 
tissues such as the lymphatic system; given the complexity of 
biological models of immune response, these data will be 
reported elsewhere. It is hoped that that the work presented 
here will be useful to the PET radiochemistry community for 
automating the radiolabelling of biomolecules of interest.
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